Physician profile
Surendra Raythatha
NPI 1407054026
$1,144.10
in general payments reported to CMS, 2019-2025
12 companies · $531 in 2025
The $531 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.00 · 2020: $46.49 · 2022: $74.77 · 2023: $174 · 2024: $248 · 2025: $531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $952.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $386.73 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Boston Scientific Corporation | $297.77 | 2019-2025 | Watchman Access System, Watchman Flx |
| Idorsia Pharmaceuticals US INC | $96.19 | 2023 | Quviviq |
| Lilly USA, LLC | $75.25 | 2022-2024 | Mounjaro |
| Abbvie INC. | $56.63 | 2022-2023 | |
| Pfizer INC. | $54.11 | 2023-2025 | |
| Exact Sciences Corporation | $53.19 | 2023-2024 | Cologuard Collection Kit |
| Inspire Medical Systems, INC. | $40.05 | 2025 | Inspire |
| Novo Nordisk INC | $28.60 | 2024-2025 | |
| Allergan, INC. | $25.42 | 2020 | |
| Amgen INC. | $16.97 | 2025 | Repatha |
| Merck Sharp & Dohme LLC | $13.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Surendra Raythatha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.